An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX® for the Symptomatic Treatment of Adults With Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice
Sponsor: Allergan
Listed as NCT01686581, this observational or N/A phase trial focuses on Migraine Disorders and remains completed. Sponsored by Allergan, it has been updated 10 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
▶ Show 5 earlier versions
-
Dec 2018 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Dec 2018 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: PHASE4 → None
-
Feb 2017 — Apr 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Anlaby, United Kingdom , Bad Camberg, Germany , Bamberg, Germany , Baunatal, Germany , Berlin, Germany , Burgos, Spain , Böblingen, Germany , Böhlen, Germany , Córdoba, Spain and 54 more locations